ReviewMaterials today. Bio2025
Harnessing macrophages for precision drug delivery and cancer therapy: Strategies, advances and challenges.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Reprogramming Autophagy to Strengthen Antitumour Immunity: Advances in Immunotherapeutic Strategies.Immunology · 2026Review
- Mannosylated graphene oxide nanotherapeutics co-delivering docetaxel and a STING agonist reprogram myeloid cells and potentiate antitumor immunity.Materials today. Bio · 2026Article
- Rewiring tumor-associated macrophages in hepatocellular carcinoma.Frontiers in immunology · 2026Review
- Macrophage-based therapeutic strategies in glioblastoma: advancements in drug delivery and immunotherapy.Frontiers in oncology · 2026Review
- Biomimetic Cell Membrane-coated Nanovaccines in Anti-tumor Immunotherapy.Theranostics · 2026Review
- Targeted delivery platforms forFrontiers in pharmacology · 2026Review
- Macrophage-Based Nanoplatforms for Tumor-Targeted Drug Delivery and Cancer Immunomodulation: Extracellular Vesicles, Membrane-Coated Nanoparticles, and Live Cells.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrophages possess inherent tumor tropism, the capacity to traverse biological barriers, and potent immunomodulatory activity, positioning them as living carriers for precision drug delivery in cancer therapy. By leveraging these properties, macrophage-based drug delivery systems mitigate persistent limitations of conventional modalities, including poor intratumoral penetration, off-target toxicity, and rapid systemic clearance. This review highlights the unique capabilities of macrophages in drug delivery, discussing their sources, preparation, and engineering strategies for enhanced therapeutic efficacy. Key advancements in drug loading methods and applications in cancer treatment are also discussed. Despite these advancements, macrophage-based systems face challenges such as immune compatibility, large-scale production, and precise control of drug release. We conclude by outlining future opportunities to harness macrophages for precision medicine, emphasizing their transformative potential in improving cancer therapy outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.